Abstract
Since May 2022, there has been a global increase in the number of Mpox virus (MPXV) cases in countries that were previously considered non-endemic. In July 2022, the World Health Organization (WHO) declared this outbreak a public health emergency of international concern. The objective of this systematic review is to examine the novel clinical features of Mpox and to assess the available treatment options for managing the disease in patients who are afflicted with it. We conducted a systematic search in several databases, including PubMed, Google Scholar, Cochrane Library, and the grey literature, from May 2022 to February 2023. We identified 21 eligible studies, which included 18,275 Mpox cases, for final qualitative analysis. The majority of cases were reported in men who have sex with men (MSM) and immunocompromised individuals with HIV (36.1%). The median incubation period was 7 days (IQR: 3–21). The novel clinical manifestations include severe skin lesions on the palms, oral and anogenital regions, as well as proctitis, penile edema, tonsillitis, ocular disease, myalgia, lethargy, and sore throat, without any preceding prodromal symptoms or systemic illness. In addition, fully asymptomatic cases were documented, and various complications, including encephalomyelitis and angina, were noted. Clinicians must be familiar with these novel clinical characteristics, as they can aid in testing and tracing such patients, as well as asymptomatic high-risk populations such as heterosexuals and MSM. In addition to supportive care, currently, there are several effective prophylactic and treatment strategies available to combat Mpox, including the vaccines ACAM2000 and MVA-BN7, as well as the immunoglobulin VIGIV and the antivirals tecovirimat, brincidofovir, and cidofovir against severe Mpox infection.
This is a preview of subscription content, access via your institution.
Data availability
Data are available from the corresponding author upon reasonable request.
Abbreviations
- ACIP:
-
Advisory Committee on Immunization Practices
- DNA:
-
Deoxyribonucleic acid
- EUA:
-
Emergency use authorization
- Ig:
-
Immunoglobulin
- HIV:
-
Human immunodeficiency virus
- STD:
-
Sexually transmitted diseases
- MPXV:
-
Mpox virus
- Mpox:
-
Monkeypox
- MSM:
-
Men who have sex with men
- RTPCR:
-
Real-time polymerase chain reaction
- VIGIV:
-
Vaccinia Immune Globulin Intravenous
- USCDC:
-
United States Centers for Disease Control
- USFDA:
-
United States Food and Drug Administration
- WHO:
-
World Health Organization
References
Monkeypox (2023) Available from: https://www.who.int/news-room/fact-sheets/detail/monkeypox. Accessed on 28
2022 Monkeypox Outbreak Global Map (2023) Available from: https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html.Accessed on: 15th
Nalca A, Rimoin AW, Bavari S, Whitehouse CA (2005) Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis 41(12):1765–1771
Jezek Z, Szczeniowski M, Paluku KM, Mutombo M (1987) Human monkeypox: clinical features of 282 patients. J Infect Dis 156(2):293–298. https://doi.org/10.1093/infdis/156.2.293
Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, Steffen R (2022) The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis 16:e0010141. https://doi.org/10.1371/journal.pntd.0010141
Mungmunpuntipantip R, Wiwanitkit V (2023 Feb) Dysphagia and Monkeypox: A Consideration. Dysphagia. 38(1):495–496. https://doi.org/10.1007/s00455-022-10481-x
United States Centers for Disease Control and Prevention (2022) Monkeypox: transmission. htt https://www.cdc.gov/poxvirus/monkeypox/transmission.html
Semba RD (2003) The ocular complications of smallpox and smallpox immunization. Arch Ophthalmol 121:715
Reynolds MG, Yorita KL, Kuehnert MJ, Davidson WB, Huhn GD, Holman RC et al (2006) Clinical manifestations of human monkeypox influenced by route of infection. J Infect Dis 194(6):773–780
United States Centers for Disease Control and Prevention. CDC and health partners resp onding to monkeypox case in the U.S. https://www.cdc.gov/media/releases/2022/s0518
United States Centers for Disease Control and Prevention (2021) CDC and Texas Confirm Monkeypox In U.S. Traveler https://www.cdc.gov/media/releases/2021/s0716-confirm-monkeypox.html
Nolen LD, Osadebe L, Katomba J, Likofata J, Mukadi D, Monroe B et al Extended human-to-human transmission during a monkeypox outbreak in the Democratic Republic of the Congo. Emery Infect Dis2016 22(6):1014–21. https://doi.org/10.3201/eid2206. 150579
World Health Organization (2022) Monkeypox fact sheet. https://www.who.int/news-room/factsheets/detail/monkeypox
Mbala PK, Huggins JW, Riu-Rovira T, Ahuka SM, Mulembakani P, Rimoin AW et al (2017) Maternal and fetal outcomes among pregnant women with human monkeypox infection in the Democratic Republic of Congo. J Infect Dis 216(7):824–828
Malik YS, Singh RK, Dhama K (eds) Animal-Origin Viral Zoonoses. Livestock Diseases and Management 2020. Springer.https://doi.org/10.1007/978-981-15-2651-0_2
WHO Director-General declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern. Available at:https://www.who.int/europe/news/item/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern. Accessed on: 30 January 2023
Huhn GD, Bauer AM, Yorita K, Graham MB, Sejvar J, Likos A et al Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin Infect Dis 2005 Dec 15;41(12):1742–51. doi: https://doi.org/10.1086/498115
Minhaj FS, Ogale YP, Whitehill F (2022) Monkeypox Outbreak - Nine States, May 2022. MMWR Morb Mortal Wkly Rep 71:764
Hammerschlag Y, MacLeod G, Papadakis G, Adan Sanchez A, Druce J, Taiaroa G et al (2022) Monkeypox infection presenting as genital rash, Australia, May 2022. Euro Surveill 27:2200411. https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200411
Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, SHARE-net Clinical Group et al (2022) Monkeypox Virus Infection in Humans across 16 Countries -April-June2022. N Engl J Med 25:387:679–691. https://doi.org/10.1056/NEJMoa2207323
TarÃn-Vicente EJ, Agud-Dios M, Alemany A, Ubals M, Suñer C, Antón A et al Clinical Presentation and Virological Assessment of Confirmed Human Monkeypox Virus Cases in Spain: A Prospective Cohort Study. Available at SSRN: https://ssrn.com/abstract=4162718 or https://doi.org/10.2139/ssrn.4162718
Orviz E, Negredo A, Ayerdi O, Vázquez A, Muñoz-Gomez A, Monzón S et al (2022 Jul) Monkeypox outbreak in Madrid (Spain): Clinical and virological aspects. J Infect 10:S0163. 4453(22)00415-7. doi: https://doi.org/10.1016/j.jinf.2022.07.005
Perez Duque M, Ribeiro S, Martins JV, Casaca P, Leite PP, Tavares M et al (2022 Jun) Ongoing monkeypox virus outbreak, Portugal, 29 April to 23 May 2022. Euro Surveill 27(22):2200424. https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200424
Iñigo MartÃnez J, Gil Montalbán E, Jiménez Bueno S, MartÃn MartÃnez F, Nieto Juliá A, Sánchez DÃaz J et al (2022) Monkeypox outbreak predominantly affecting men who have sex with men, Madrid, Spain, 26 April to 16 June 2022. Euro Surveill 27:2200471. https://doi.org/10.2807/1560-7917.ES.2022.27.27.2200471
Miura F, van Ewijk CE, Backer JA, Xiridou M, Franz E, Op de Coul E et al (2022 Jun) Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022. Euro Surveill 27(24):2200448. https://doi.org/10.2807/1560-7917.ES.2022.27.24.2200448
Peiró-Mestres A, Fuertes I, CamprubÃ-Ferrer D, Marcos M, Vilella A, Navarro M, Hospital Clinic de Barcelona Monkeypox Study Group et al (2022 Jul) Frequent detection of monkeypox virus DNA in saliva, semen, and other clinical samples from 12 patients, Barcelona, Spain, May to June 2022. Euro Surveill 27(28). https://doi.org/10.2807/1560-7917.ES.2022.27.28.2200503
Girometti N, Byrne R, Bracchi M, Heskin J, McOwan A, Tittle V et al Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis. Lancet Infect Dis 2022 Jul 1:S1473-3099(22)00411-X. doi: https://doi.org/10.1016/S1473-3099(22)00411-X
Patel A, Bilinska J, Tam JCH, Da Silva Fontoura D, Mason CY, Daunt A et al Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series. BMJ 2022 Jul 28;378:e072410. doi: https://doi.org/10.1136/bmj-2022-072410
Antinori A, Mazzotta V, Vita S (2022) Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. Euro Surveill 27(22):2200421. https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200421
Reynolds MG, McCollum AM, Nguete B, Shongo Lushima R, Petersen BW (2017) Improving the Care and Treatment of Monkeypox Patients in Low-Resource Settings: Applying Evidence from Contemporary Biomedical and Smallpox Biodefense Research. Viruses 9:380. https://doi.org/10.3390/v9120380
Smith JA, Casey CG, Tierney BC (2004) Sep;122(9):1407 The ocular complications of smallpox and smallpox immunization. Arch Ophthalmol. ; author reply 1407-8. doi: https://doi.org/10.1001/archopht.122.9.1407-a
United States Centers for Diseae Control and Prevention (2022) Interim clinical guidance for the treatment of monkeypox. https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html (Accessed on 30
World Health Organization (2022) Clinical management and infection prevention and control for monkeypox. Interm rapid response guidance. 10 June 2022. https://www.who.int/publications/i/item/WHO-MPX-Clinical-and-IPC-2022.1 (Accessed on 30
Altmann S, Brandt CR, Murphy CJ, Patnaikuni R, Takla T, Toomey M et al (2011) Evaluation of therapeutic interventions for vaccinia virus keratitis. J Infect Dis 203(5):683–690. https://doi.org/10.1093/infdis/jiq103
Abdelaal A, Serhan HA, Mahmoud MA, Rodriguez-Morales AJ, Sah R (2022) Ophthalmic manifestations of monkeypox virus. Eye (Lond). 27. https://doi.org/10.1038/s41433-022-02195-z
Fine PE, Jezek Z, Grab B, Dixon H (1988) The transmission potential of monkeypox virus in human populations. Int J Epidemiol 643–650. https://doi.org/10.1093/ije/17.3.643
WHO.Vaccines and immunization for monkeypox. file:///C:/Users/Admin/Downloads/WHO-MPX-Immunization-2022.1-eng%20(1).pdf.
FDA approves the first (2022) drug with an indication for treatment of smallpox. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613496.html(Accessed
Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM et al (2009 May) ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother 53(5):1817–1822
Adler H, Gould S, Hine P et al (2022) Clinical features and management of human monkeypox. Lancet Infect Dis 22(8):1153–1162. https://doi.org/10.1016/S1473-3099(22)00228-6
Merchlinsky M, Albright A, Olson V, Schiltz H, Merkeley T, Hughes C, Petersen B, Challberg M (2019) The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpox. Antiviral Res 168–174. https://doi.org/10.1016/j.antiviral.2019.06.005
Rao AK, Schulte J, Chen TH et al (2022) Monkeypox in a Traveler Returning from Nigeria - Dallas, Texas, July 2021. MMWR Morb Mortal Wkly Rep 71:509
Baker RO, Bray M, Huggins JW (2003) Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res 57:13
Andrei G, Snoeck R (2010) Cidofovir Activity against Poxvirus Infections. Viruses 2:2803–2830. https://doi.org/10.3390/v2122803
Hopkins RJ, Lane JM Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin Infect Dis 2004 Sep 15;39:819–26. doi: https://doi.org/10.1086/422999
Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA (2003) Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 37:251–271
Hutson CL, Kondas AV, Mauldin MR, Doty JB, Grossi IM, Morgan CN et al (2021) Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model. mSphere e00927–e00920. https://doi.org/10.1128/mSphere.00927-20
Pittman PR et al (2019) Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox. N Engl J Med 381:1897–1908
Khalil A, Samara A, O'Brien P, Morris E, Draycott T, Lees C, Ladhani S Monkeypox vaccines in pregnancy: lessons must be learned from COVID-19. Lancet Glob Health. 2022:S2214-109X(22)00284-4. doi: https://doi.org/10.1016/S2214-109X(22)00284-4
ACAM (2000) (Smallpox (Vaccinia) Vaccine, Live) Lyophilized preparation for percutaneous scarification.available from:https://www.fda.gov/media/75792/download
Daniel R Lucey.The two-dose monkeypox vaccine,JYNNEOS,licensed by FDA in 2019. Accessedon:https://www.idsociety.org/science-speaks-blog/2022/the-two-dose-monkeypox-vaccine-jynneos-licensed-by-fda-in2019/#/+/0/publishedDate_na_dt/desc/
Eto A, Yamamoto N, Kanatani Y Effect of Serial Passage on the Pathogenicity and Immunogenicity of Vaccinia Virus LC16m8 Strain. Biology (Basel). 2021 Nov 9;10(11):1158. doi: https://doi.org/10.3390/biology10111158
Lansiaux E et al The Virology of Human Monkeypox Virus (hMPXV): A Brief Overview. Virus Res 2022 Dec ;322:198932. doi: https://doi.org/10.1016/j.virusres.2022.198932
Monkeypox vaccine from Bavarian Nordic wins EU approval. Available from:https://www.reuters.com/business/healthcare-pharmaceuticals/bavarian-nordic-monkeypox-vaccine-wins-eu-approval-2022-07-25/
WHO (2022) 2022, World Health Organization. Available on: file:///C:/Users/Admin/Downloads/WHO-MPX-Immunization-2022.1-eng.pdf. accessed on 28 July 2022
Joint ECDC-, WHO Regional Office for Europe Monkeypox Surveillance Bulletin (2022) Available at: https://monkeypoxreport.ecdc.europa.eu/.
Chenchula S, Karunakaran P, Sharma S, Chavan M (2022) Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. J Med Virol 94:2969–2976. https://doi.org/10.1002/jmv.27697
Chenchula S, Amerneni KC, Ghanta MK, et al. Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub-variant BF.7 (BA.5.2.1.7): A systematic review. Virology. 2023;584:38–43. https://doi.org/10.1016/j.virol.2023.04.007
Desai AN, Thompson GR 3rd, Neumeister SM, Arutyunova AM, Trigg K, Cohen SH Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection. JAMA 2022 Oct 4;328(13):1348–1350. doi: https://doi.org/10.1001/jama.2022.15336
Monkeypox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply. Available at: https://www.fda.gov/media/160774/download#:~:text=Information%20Regarding%20Available%20Alternatives%20for,for%20smallpox%20or%20monkeypox%20infection
De Baetselier I, Van Dijck C, Kenyon, Coppens J, Michiels J, de Block TC et al (2022) Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium. Nat Med 28;2288–92. https://doi.org/10.1038/s41591-022-02004-w
Ferré VM, Bachelard A, Zaidi M, Armand-Lefevre L, Descamps D, Charpentier C et al (2022) Detection of Monkeypox Virus in Anorectal Swabs from Asymptomatic Men Who Have Sex With Men in a Sexually Transmitted Infection Screening Program in Paris, France. Ann Intern Med. https://doi.org/10.7326/M22-2183
TarÃn-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suñer C, Antón A et al Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lancet. 2022 Aug 27;400(10353):661-9. doi: https://doi.org/10.1016/S0140-6736(22)01436-2
Girometti N, Byrne R, Bracchi M, Heskin J, McOwan A, Tittle V et al (2022) Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis. Lancet Infect Dis 1321–1328. https://doi.org/10.1016/S1473-3099(22)00411-X
Mailhe M, Beaumont AL, Thy M, Le Pluart D, Perrineau S, Houhou-Fidouh N et al (2023) Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study. Clin Microbiol Infect 233–239. https://doi.org/10.1016/j.cmi.2022.08.012
Palich R, Burrel S, Monsel G, Nouchi A, Bleibtreu A, Seang S et al Viral loads in clinical samples of men with monkeypox virus infection: a French case series. Lancet Infect Dis 2023 Jan;23(1):74–80. doi: https://doi.org/10.1016/S1473-3099(22)00586-2
Cassir N, Cardona F, Tissot-Dupont H, Bruel C, Doudier B, Lahouel S et al (2022) Observational Cohort Study of Evolving Epidemiologic, Clinical, and Virologic Features of Monkeypox in Southern France. Emerg Infect Dis 28(12):2409–2415. https://doi.org/10.3201/eid2812.221440
Gomez-Garberi M, Sarrio-Sanz P, Martinez-Cayuelas L, Delgado-Sanchez E, Bernabeu-Cabezas S, Peris-Garcia J et al (2022 Dec) Genitourinary Lesions Due to Monkeypox. Eur Urol 82(6):625–630. https://doi.org/10.1016/j.eururo.2022.08.034
Russo AT, Grosenbach DW, Chinsangaram J, Honeychurch KM, Long PG, Lovejoy C et al (2021) An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther 19(3):331–344. https://doi.org/10.1080/14787210.2020.1819791
Halani S, Leong D, Wu PE (2022) Tecovirimat for monkeypox. CMAJ 194(46):E1573. https://doi.org/10.1503/cmaj.221210
Rubio-Muniz CA, Montero-Menárguez J, López-Valle A, Agud-Dios M, Arroyo-Andrés J, Rodriguez-Peralto JL et al Monkeypox: is topical cidofovir a good idea? Clin Exp Dermatol. 2023 Feb 2;48(2):132 – 34. doi: https://doi.org/10.1093/ced/llac038
Sudarmaji N, Kifli N, Hermansyah A, Yeoh SF, Goh BH, Ming LC (2022) Prevention and Treatment of Monkeypox: A Systematic Review of Preclinical Studies. Viruses 14(11):2496. https://doi.org/10.3390/v14112496
McLean J, Stoeckle K, Huang S, Berardi J, Gray B, Glesby MJ, Zucker J. Tecovirimat Treatment of People With HIV During the 2022 Mpox Outbreak: A Retrospective Cohort Study. Ann Intern Med. 2023 May;176(5):642-648. https://doi.org/10.7326/M22-3132
Chenchula S, Vidyasagar K, Pathan S, et al. Global prevalence and effect of comorbidities and smoking status on severity and mortality of COVID-19 in association with age and gender: a systematic review, meta-analysis and meta-regression. Sci Rep. 2023;13(1):6415.
Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A, Ihekweazu C et al (2019) Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention. Infect Dis Clin North Am 33(4):1027–1043. https://doi.org/10.1016/j.idc.2019.03.001
Poland GA, Kennedy RB, Tosh PK (2022) Prevention of monkeypox with vaccines: çåa rapid review. Lancet Infect Dis e349–e358. https://doi.org/10.1016/S1473-3099(22)00574-6
Funding
None to declare
Author information
Authors and Affiliations
Contributions
All authors meet the ICMJE criteria for authorship. SC and MG conducted the literature search and data extraction and drafted the manuscript. KCA, PR, MBC, MRC, and RG revised the manuscript. All authors have reviewed and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Additional information
Communicated by William G. Dundon
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic Supplementary Material
Below is the link to the electronic supplementary material
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chenchula, S., Ghanta, M.K., Amerneni, K. et al. A systematic review to identify novel clinical characteristics of monkeypox virus infection and therapeutic and preventive strategies to combat the virus. Arch Virol 168, 195 (2023). https://doi.org/10.1007/s00705-023-05808-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00705-023-05808-4